“Concurrent EGFR and KRAS mutations in non-small cell lung cancer: Challenging the paradigm of linear targeted therapy” (2025) Journal of Current Biomedical Reports, 6(2), pp. 45–46. doi:10.61882/jcbior.6.2.299.